https://www.selleckchem.com/products/fg-4592.html
The 5-year overall survival was 88% in the IGRT arm and 86% in the non-IGRT arm (adjusted hazard ratio [HR] of death = 0.93; 95% CI, 0.61-1.45; = 0.77). The SA also showed no significant differences in the overall survival between those in the IGRT and non-IGRT arms. Both groups did not significantly differ in terms of IPCM, IOCM, and ICVM. The overall survival of localized prostate cancer patients who underwent IGRT was not inferior to those who did not. We demonstrated that the overall survival for prostate cancer patients with IGRT w
Like
Comment
Share
